Genetic Engineering & Biotechnology News recently ran a brief article entitled “EU Sanctions Merck & Co.’s Sublingual Bipolar Disorder Drug Sycrest.” Sycrest was first approved in the U.S. in 2009 where Merck markets it as Saphris. Sycrest/Saphris is a “sublingual asenapine drug for treating moderate to severe manic episodes in adult patients with bipolar I disorder” and for treating schizophrenia. When used in treating bipolar disorder mania, it is most effective when used with other anti-manic medications, including lithium and Depakote.

Saphris/asenapine is the newest member of the class of drugs called atypical antipsychotics. It works in the same general manner – affecting primarily dopamine receptors. It also carries the same potential risks that we describe in our initial post on atypical antipsychotics. It is approved for use in schizophrenia and Bipolar I disorder for acute mania. It comes in a sublingual form (under the tongue), which some patients prefer, but which many people don’t like.

I have only had the opportunity to try it in one patient and she experienced severe sedation and stopped it. It was otherwise well tolerated. My thoughts at this point are that because this is a new medicine, with unknown safety profile in longer term use, it is probably going to be used primarily in individuals who have not responded to anything else for their condition.

The primary reason for using Saphris instead of one of the other atypical antipsychotics would be if Saphris were less prone than the others to cause weight gain. Unfortunately, Saphris has not proven much better than other atypical antipsychotics at avoiding this bothersome side effect.

 


Comments


View Comments / Leave a Comment

This post currently has 9 comments.
You can read the comments or leave your own thoughts.

Trackbacks

No trackbacks yet to this post.






    Last reviewed: 9 Sep 2010

APA Reference
Fink, C. (2010). Bipolar Disorder Medication Spotlight: Saphris. Psych Central. Retrieved on October 25, 2014, from http://blogs.psychcentral.com/bipolar/2010/09/bipolar-disorder-medication-spotlight-saphris/

 

Bipolar Beat


Subscribe to this Blog:
Feed

Bipolar
Disorder



Archives





Candida Fink, M.D. and Joe Kraynak are authors of
Bipolar Disorder for Dummies.


Best of the Web - Blog 2008

Subscribe to this Blog: Feed

Recent Comments
  • T: what’s best is to ask HER! its an illness not a retardation… just dont ask her while she is in an...
  • B: Absolutely. Trouble is, the Pharma companies probably own shares in the food companies we purchase from when the...
  • B: Like many contributors to this discussion, I thought I was very much alone in this weight gain. I gained about 15...
  • candice: I take lexapro 10mg once a day. I have been diagnosed with major depressive disorder with psychotic...
  • Victoria: Hello Jil – what you wrote resonates so true with me. I grew up in constant fear because Mum was...
Find a Therapist
Enter ZIP or postal code



Users Online: 12240
Join Us Now!